Asset Purchase Deals in Pharmaceuticals and Biotechnology 2016-2024: Trends, Deal Structure, Leading Deals by Value, Most Active Dealmakers, and More
Dublin, March 08, 2024 (GLOBE NEWSWIRE) -- The "Asset Purchase Deals in Pharmaceuticals and Biotechnology 2016-2024" report has been added to ResearchAndMarkets.com's offering.
Asset Purchase Deals in Pharmaceuticals and Biotechnology is intended to provide the reader with an in-depth understanding of the asset purchase trends and structure of deals entered into by leading biopharma companies worldwide.
Asset Purchase Deals in Pharmaceuticals and Biotechnology includes:
Trends in asset purchase dealmaking in the biopharma industry
Overview of asset purchase deal structure
Directory of asset purchase deal records covering pharmaceutical and biotechnology
The leading asset purchase deals by value
Most active asset purchase dealmakers
The leading asset purchase partnering resources
In Asset Purchase Deals in Pharmaceuticals and Biotechnology, the available deals are listed by:
Company A-Z
Headline value
Therapeutic area
Technology type
Each deal title links via Weblink to an online version of the actual deal record, providing easy access to each contract document where available.
Asset Purchase Deals in Pharmaceuticals and Biotechnology provides comprehensive access to available records for asset purchase deals, including contract documents where available.
Analyzing contract agreements allows due diligence of:
What are the rights granted or optioned?
What rights are granted by the agreement?
What exclusivity is granted?
What is the payment structure for the deal?
How are sales and payments audited?
What is the deal term?
How are the key terms of the agreement defined?
How are intellectual property rights handled and owned?
Who is responsible for commercialization?
Who is responsible for development, supply, and manufacture?
How is confidentiality and publication managed?
How are disputes resolved?
Under what conditions can the deal be terminated?
What happens when there is a change of ownership?
What sublicensing and subcontracting provisions have been agreed?
Which boilerplate clauses does the company insist upon?
Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
Which jurisdiction does the company insist upon for agreement law?
Companies Mentioned
3CL Sciences
3SBio
4D Molecular Therapeutics
4SC
9 Meters Biopharma
30 Technology
Aardvark Therapeutics
Abbvie
Abcam
AbCellera Biologics
Acacia Research
Accord
Acelity
Achaogen
AC Immune
Acino Pharma
Aclaris Therapeutics
Acorda Therapeutics
Acrotech Biopharma
Actavis (acquired by Watson)
Adalvo
Adamis Pharmaceuticals
Adello Biologics
Adhera Therapeutics
Adial Pharmaceuticals
ADMA Biologics
adMare BioInnovations
Adovate
Advanced Neural Dynamics
Advanced Tear Diagnostics
Advanomics
ADvantage Therapeutics
Advanz Pharma
Advent International
Advicenne
Aerie Pharmaceuticals
Aethon Therapeutics
Aevitas Therapeutics
AFFiRiS
AGC Asahi Glass
AGC Biologics
AgeX Therapeutics
Agios Pharmaceuticals
Agrium
AiPing Pharmaceutical
Akkadeas Pharma
Akorn
Akoya Biosciences
Akrimax Pharmaceutical
Alaya.bio
Albumedix
Alcon Laboratories
Aleph Farms
Alexion Pharmaceuticals
Alexza Pharmaceuticals
Alfasigma
Algernon Pharmaceuticals
AliveGen
ALK-Abello
Allegis Pharmaceuticals
Allergan
Allergan Aesthetics
Alliance Pharma
Ally Biotech
Almirall
Alphagen Laboratories
Alpine Immune Sciences
Altaris Capital Partners
Altavant Sciences
Altermune Technologies
Alvine Pharmaceuticals
Alvogen
Amarantus BioSciences
Amerigen Pharmaceuticals
AmerisourceBergen
Amgen
Amneal Pharmaceuticals
Amphastar Pharmaceuticals
Amplifybio
AmpliPhi Biosciences
Amplyx Pharmaceuticals
AMP Therapeutics
Amring Pharmaceuticals
Amygdala Neurosciences
Amyris
Angelini Pharma
ANI Pharmaceuticals
Antares Pharma
ApoPharma
Apotex
Applied Biology
Aptevo Therapeutics
APT Therapeutics
Aradigm
Aralez Pharmaceuticals
Araris Biotech
aratinga.bio SAS Group
Arcadia Consumer Healthcare
argenx
ArisGlobal
and 884 more players!
For more information about this report visit https://www.researchandmarkets.com/r/81vdo2
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood,Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900